Evidence map›Paper›PMID 41827890›Full record

ArticleCells2026

Cys340Ser Mutation Abolishing S-Nitrosylation Drives GRK2 Mitochondrial Localization and Dysfunction.

Gizem Kayki Mutlu, Stephanie M Kereliuk, Maya Hoteit, J Kurt Chuprun, Umur Mendes, Yusuf Olgar, Walter J Koch

Abstract read
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gizem Kayki MutluDepartment of Pharmacology, Faculty of Pharmacy, Ankara University, Tandogan, 06100 Ankara, Turkey.ORCID 0000-0002-3177-9438
Stephanie M KereliukDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0293-5646
Maya HoteitDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
J Kurt ChuprunDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Umur MendesDepartment of Pharmacology, Faculty of Pharmacy, Ankara University, Tandogan, 06100 Ankara, Turkey.
Yusuf OlgarDepartment of Biophysics, Faculty of Medicine, Ankara University, 06620 Ankara, Turkey.ORCID 0000-0002-3226-7450
Walter J KochDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-8522-530X

Funding

National Heart Lung and Blood Institute R01HL157151
6 · The paper itself

Abstract

In cardiac pathologies, levels of G protein-coupled receptor kinase 2 (GRK2)-which is involved in receptor desensitization and internalization-are elevated. Beyond these receptor-mediated effects, GRK2 also localizes to mitochondria, where it contributes to pathology. GRK2's activity can be inhibited via S-nitrosylation at Cysteine 340, a post-translational modification mediated by both endogenous and exogenous nitric oxide. Thus, S-nitrosylation is considered as an endogenous brake on GRK2's catalytic activity, counteracting its hyperactivity observed in disease states. However, it remains unclear whether S-nitrosylation also regulates GRK2's influence on mitochondrial function. This study aims to investigate how S-nitrosylation regulates mitochondrial localization and function of GRK2 under hypoxia/reoxygenation stress. To prevent S-nitrosylation at Cys340, we infected AC16 cardiac cells with adenoviruses carrying a GRK2 C340S (Ser) mutation. Our results indicate that inhibiting S-nitrosylation enhances mitochondrial localization of GRK2, especially in response to pathological stimuli. Additionally, mitochondrial function was impaired, as measured by oxygen consumption rates at ATP production. Furthermore, alterations in mitochondrial dynamics and mitophagy led to adverse outcomes when GRK2 was not subject to S-nitrosylation, presumably due to increased catalytic activity. Our findings underscore the importance of GRK2 regulation in cardiac pathologies and suggest that targeting GRK2 or its post-translational modifications may provide therapeutic benefits.

Indexed as

CysteineG-Protein-Coupled Receptor Kinase 2MitochondriaMutationAnimalsCell LineHumansMyocytes, CardiacNitric OxideOxygen ConsumptionProtein Processing, Post-TranslationalCysteineG-Protein-Coupled Receptor Kinase 2Nitric OxideGRK2hypoxia/reoxygenationmitochondriaS-nitrosylation

Identifiers

PMID41827890
PMCPMC12984605

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.